贝前列素钠对糖尿病肾病患者血浆内皮素1水平的影响

目的观察贝前列素钠对糖尿病肾病患者临床疗效及血浆内皮素1水平的影响。方法选择2型糖尿病患者75例，根据是否合并糖尿病肾病将其分为无肾病组（27例）和肾病组（48例）。将’肾病组患者完全随机分为对照组和研究组，各24例。在常规治疗的基础上，研究组另用贝前列素钠20仙g／次，1次／d，口服。用药前及用药后8周测定3组糖尿病患者血浆内皮素1水平、尿微量白蛋白及尿白蛋白排泄率（UAER）。结果肾病组和无肾病组用药前血浆内皮素1分别为（138±9）ng／L和（67±3）ng／L，差异有统计学意义（P〈0．01）。研究组应用贝前列素钠后血浆内皮素1和UAER明显低于对照组，组间差异有统计学意义血浆内皮素1：（72±4）比（126±9）ng／L，P〈0．05；UAER：（89±27）比（109±35）mg／24h，P〈0．01]。结论内皮素1水平升高在糖尿病肾病的发病中发挥重要作用。贝前列素钠治疗可纠正糖尿病’肾病患者血浆内皮素1平衡失调，改善糖尿病肾病内皮功能，降低尿蛋白，对糖尿病。肾病有保护作用。

Effects of beraprost sodium on plasma ET-1 in patients with diabetic nephropathy

Objective To observe the effect of beraprost sodium on diabetic nephropathy （DN） patients and to observe if beraprost sodium in patients with diabetic nephropathy affects the level of endothelin-1. Methods Totally 75patients with type 2 diabetes with or without diabetic nephropathy were divided into non-diabetic nephropathy group （n = 27 ） and diabetic nephropathy group （48 cases）. Nephrotic patients were randomly divided into control group and study group with 24 cases in each group. Determination of diabetic patients plasma levels of endothelin-1, beraprost sodium and plasma endothelin-1, urinary albumin and urinary albumin excretion rate （UAER） levels was made. Results Plasma endothelin-1 in nephropathy group was significantly higher than that in non-nephropathy group and the difference was statistically significant （ P 〈 0. 01 ）. Beraprost sodium, plasma endothelin-1 and UAER were significantly lower than those in control group and the difference was statistically significant. Conclusions The level of ET-1 may play an important role in the onset of diabetic nephropathy. Beraprost sodium can improve endothelial function and decrease urine protein in diabetic nephropathy.